First in class oncology drugs for unmet need

Ymmunobio AG

Incorporated

07.09.2021

Headquarters

Riehen

Support

Ymmunobio has identified a new tumor marker with superior properties:
1. It is present in at least 13 solid tumors
2. It has a prevalence of up to 98% in cancer patients
3. It is not expressed by normal tissue
Ymmunobio has built a complete development program around this novel target featuring three therapeutic antibodies:
1. YB-800ADC, an ADC with linkers of the 3rd generation
2. YB-800R1&2, 2 radio pharmaceuticals in collaboration with the Paul Scherrer Institut (PSI) supported by an Innosuisse grant
3. YB-800BS1&2, 2 bi-specific antibody with an aCD3 T-cell engager
In addition, Ymmunobio is also developing two companion diagnostics, one for SPECT imaging (with PSI) and one blood test for cancer screening and patient eligibility (with EVIIVE)